Entrada Therapeutics (TRDA) EBITDA (2020 - 2026)

Entrada Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$42.3 million for Q1 2026.

• In Q1 2026, EBITDA fell 94.14% year-over-year to -$42.3 million; the TTM figure through Mar 2026 stood at -$178.4 million (down 4443.01% YoY), while the FY2025 annual figure was -$157.9 million, down 435.87% from the prior year.
• EBITDA for Q1 2026 stood at -$42.3 million, roughly flat from -$42.2 million in the prior quarter.
• The five-year high for EBITDA was $53.4 million in Q2 2024, with the low at -$47.1 million in Q3 2025.
• The 5-year median for EBITDA is -$21.8 million (2025), against an average of -$14.9 million.
• The sharpest annual moves came in 2024 and 2025: EBITDA jumped 465.28% in 2024, then plunged 619.41% in 2025.
• Entrada Therapeutics' EBITDA stood at -$25.6 million in 2022, then jumped by 119.18% to $4.9 million in 2023, then tumbled by 219.61% to -$5.9 million in 2024, then slumped by 619.41% to -$42.2 million in 2025, then declined by 0.23% to -$42.3 million in 2026.
• Business Quant data shows TRDA's EBITDA at -$42.3 million in Q1 2026, -$42.2 million in Q4 2025, and -$47.1 million in Q3 2025.